INSITE-DME: Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial
Study Details
Study Description
Brief Summary
This study will assess a pragmatic, treat and extend regimen of faricimab against the standard of a fixed dosing regimen.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 4 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Treat and Extend Participants randomized to the T&E Arm will initially receive 6 milligrams (mg) faricimab intravitreal (IVT) injections monthly (28d +/-7 days), with treatment intervals increased/extended, reduced, or maintained based on CST assessments, until week 100. |
Drug: Faricimab
Faricimab will be administered via intravitreal injection.
|
| Other: Control/Usual Care Arm Participants in the control arm will receive 6 milligrams (mg) faricimab intravitreal (IVT) injections monthly (28d +/-7 days), for 6 treatments. Afterwards, participants will continue to receive 6mg faricimab IVT every 8 weeks until week 100. |
Drug: Faricimab
Faricimab will be administered via intravitreal injection.
|
Outcome Measures
Primary Outcome Measures
- Change in Best Corrected Visual Acuity [Baseline to Week 100]
Change in best corrected visual acuity (3.9 letter non-inferiority margin)
Secondary Outcome Measures
- Decrease in Diabetic Retinopathy Severity Score [Baseline to Week 100]
A 2-step improvement in diabetic retinopathy severity score
- Decrease in Diabetic Retinopathy Severity Score [Baseline to Week 100]
A 3-step improvement in diabetic retinopathy severity score
- Change in Central Subfield Thickness [Baseline to Week 100]
Change in central subfield thickness on OCT
- Change in Vision Related Quality of Life [Baseline to Week 100]
Change in vision-related quality of life (VFQ-25)
- Change in Letters of Vision [Baseline to Week 100]
Gaining or losing ≥5, ≥10, or ≥15 letters of vision
- Absence of Diabetic Macular Edema [Week 100]
Absence of diabetic macular edema in the study eye
- Absence of Intraretinal Fluid (IRF) [Week 100]
Absence of intraretinal fluid (IRF) in the study eye
- Dosing Interval [Week 100]
Dosing interval at week 100
- Presence of Safety Outcomes [Baseline to Week 100]
Safety outcomes (ocular and systemic AEs and SAEs)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥ 18 years
-
Diagnosis of diabetes mellitus (type 1 or type 2).
-
Macular thickening secondary to DME (CI-DME) involving the center of the fovea on Optical Coherence Tomography - Central subfield thickness (CST) ≥ 325 μm on Spectralis at screening.***
-
Visual impairment due to DME, with best corrected visual acuity of 80 to 20 letters (Snellen VA 20/25 - 20/400).
-
Media clarity, pupillary dilation, and individual cooperation sufficient for adequate OCT and fundus photographs.
-
Hemoglobin A1c must be <10% within 2 months prior to 1st study treatment.
-
Provide signed informed consent.
Exclusion Criteria:
-
Active or history of ocular inflammation or suspected/active ocular infection in either eye.
-
High-risk proliferative diabetic retinopathy in the study eye.**
-
Tractional retinal detachment, preretinal fibrosis or visually significant epiretinal membrane involving the macula.
-
Uncontrolled glaucoma (intraocular pressure >30 with or without medications).
-
Any intravitreal, periocular or implant corticosteroids within 26 weeks (6 months) before day 1 or any use of Iluvien implants.
-
Treatment with Panretinal photocoagulation (PRP) within 12 weeks before day 1.
-
Treatment with macular laser.
-
Any cataract surgery or any other intraocular surgery within 12 weeks before day 1.
-
Macular edema in study eye due to a cause other than DME.
-
If clinical exam and/or OCT and/or wide-field fluorescein angiography (WF-FA) suggest that (a) macular edema is considered to be related to ocular surgery such as cataract extraction or (b) if primary cause for macular edema is vitreoretinal interface abnormalities (e.g. a taut posterior hyaloid or epiretinal membrane).
-
Any ocular condition is present such that visual acuity loss would not improve from resolution of macular edema in opinion of the investigator (e.g. foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, nonretinal condition)
-
Any history of ocular conditions that might affect macular edema (e.g. vein occlusion, idiopathic or infectious or non-infectious uveitis, ocular inflammatory disease, neovascular glaucoma etc.)
-
Women of child-bearing potential who are lactating, pregnant, or intending to become pregnant within the next 100 weeks.
-
Current or anticipated incarceration.
-
Terminal illness with expected survival less than 100 weeks.
-
Known hypersensitivity to faricimab or any of the excipients in the faricimab injection.
-
Currently enrolled in a study that does not permit co-enrollment.
-
Unable to obtain informed consent due to language or other operational barriers.
-
Anticipated problems, in the judgment of the site investigator, maintaining compliance with the protocol, including attending study visits, completing assessments or procedures.
-
Prior enrollment in this trial.
-
Other reason to exclude the patient, as approved by the sponsor and site investigator.
-
Previous treatment with anti-VEGF and:
-
<12 weeks prior to day 1 (washout period).*or,
-
Diagnosis of DME is > 2 years of enrollment or,
-
Do not have a demonstrated response to anti-VEGF treatment based on clinical discretion.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- McMaster University
- Hoffmann-La Roche
Investigators
- Principal Investigator: Dr. Varun Chaudhary, MD, FRCS(C), McMaster University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2022-01
- MR44143